Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-032 in Adults With Cystic Fibrosis
NCT06747858Phase 2Recruiting
- Sponsor
- Arcturus Therapeutics
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ARCT-032 in cystic fibrosis (CF), sponsored by Arcturus Therapeutics. Started Dec 2024; status: recruiting.
02
Drugs
ARCT-032
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT06747858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747858.